Corporate News: Alkermes PLC
Alkermes PLC (ticker ALKS) traded up 2.65 % during the 24‑hour period ending at 03:47 PM Central Europe on Wednesday, 21 October 2026. At the close, one share was priced at approximately USD 44.37 on major exchanges. The company’s total share supply stands at 167.8 million, yielding a market capitalisation of USD 7.2 billion. In the last 24 hours, roughly USD 97.1 million of Alkermes shares changed hands.
Recent Performance Context
Since the close of the previous month, Alkermes shares have slipped by 0.16 %. The 200‑day simple moving average is USD 39.87, suggesting that the recent price action is well above the medium‑term trend. The all‑time high for the past 52 weeks was USD 55.67 on 7 July 2026, while the 52‑week low was USD 27.00 on 19 March 2026.
Market observers noted that the 4.2 % uptick in the company’s share price attracted attention from investors monitoring broader market indicators. Analysts pointed out that Alkermes’ valuation metrics—derived from financial data platforms—indicated a valuation level that exceeds the current trading price, hinting at potential upside in the near term. The rally was attributed to a blend of positive market sentiment and favorable comparisons with peers in the pharmaceutical sector.
Comparable Movements in the Sector
| Stock | 24‑Hour Move | Current Price | Market Capitalisation | P/E Ratio | Recent Corporate Action |
|---|---|---|---|---|---|
| Glenveagh Properties (GLV.L) | +0.43 % | €2.36 | €1.2 bn | 15.23 | Completed share buy‑back (12‑16 Oct 2026) |
| Glanbia (GL9.IR) | –0.69 % | €20.36 | €4.8 bn | 14.38 | No recent action |
| Permanent Tsb (PTSB.IR) | 0 % | €2.98 | €1.7 bn | 16.15 | Filed Irish Takeover Panel disclosures (20‑21 Oct 2026) |
| Greencoat Renewables (GRP.IR) | 0 % | €0.79 | €859.2 mn | – | – |
These movements illustrate the broader market environment in which Alkermes operates. While some peers are engaging in share‑buyback programmes or filing regulatory disclosures, Alkermes’ recent price action remains largely driven by intrinsic company fundamentals and sector sentiment.
Company Overview
Alkermes PLC is a biotechnology firm headquartered in Dublin 4, Ireland, listed on the Nasdaq stock exchange. The company focuses on developing therapeutics for central nervous system disorders—including addiction, schizophrenia, and depression—as well as diabetes. Its initial public offering was dated 16 July 1991. For more detailed information, visit the company’s website at www.alkermes.com .
